StockData
Lexicon Pharmaceuticals, Inc. logo

Lexicon Pharmaceuticals, Inc. (LXRX) income statement

LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3082% above fair value
$1.72−0.06 (-3.37%)

Close on Nov 18, 2026Market cap $765.32MP/E –Yield –

Lexicon Pharmaceuticals, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
99.1%
Operating margin
-131.4%
Net margin
-147.4%
Return on equity, FY2025
-39.7%

Financial strength

Current ratio
13.37
Debt to equity
0.29
Debt to assets
20.6%
Cash to current liabilities
278.3%

Valuation

P/E ratio
–
Price to sales
18.46
Price to book
4.39
Dividend yield
–

See a number that looks wrong?